Overview |
bsm-52181r-100ul |
TP53 Recombinant Antibody |
WB, IHC-P |
Human |
Specifications |
Unconjugated |
Rabbit |
KLH conjugated Synthesised phosphopeptide derived from human TP53 around the phosphorylation site of Ser376:GQ(p-S)TS. |
S376 |
Recombinant |
IgG |
1ug/ul |
Purified by Protein A. |
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
Shipped at 4℃. Store at -20℃ for one year. Avoid repeated freeze/thaw cycles. |
Target |
7157 |
P04637 |
P53; BCC7; LFS1; TRP53; Cellular tumor antigen p53; Antigen NY-CO-13; Phosphoprotein p53; Tumor suppressor p53; TP53 |
Acts as a tumor suppressor in many tumor types; induces growth arrest or apoptosis depending on the physiological circumstances and cell type. Involved in cell cycle regulation as a trans-activator that acts to negatively regulate cell division by controlling a set of genes required for this process. One of the activated genes is an inhibitor of cyclin-dependent kinases. Apoptosis induction seems to be mediated either by stimulation of BAX and FAS antigen expression, or by repression of Bcl-2 expression. In cooperation with mitochondrial PPIF is involved in activating oxidative stress-induced necrosis; the function is largely independent of transcription. Induces the transcription of long intergenic non-coding RNA p21 (lincRNA-p21) and lincRNA-Mkln1. LincRNA-p21 participates in TP53-dependent transcriptional repression leading to apoptosis and seem to have to effect on cell-cycle regulation. Implicated in Notch signaling cross-over. Prevents CDK7 kinase activity when associated to CAK complex in response to DNA damage, thus stopping cell cycle progression. Isoform 2 enhances the transactivation activity of isoform 1 from some but not all TP53-inducible promoters. Isoform 4 suppresses transactivation activity and impairs growth suppression mediated by isoform 1. Isoform 7 inhibits isoform 1-mediated apoptosis. |
Application Dilution |
WB |
1:300-5000 |
IHC-P |
1:200-400 |